NCT02697383View on ClinicalTrials.gov

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 8, 2024

Study Completion Date

May 8, 2024

Conditions
Multiple MyelomaHigh Risk Smoldering Multiple Myeloma
Interventions
DRUG

Ixazomib (MLN9708)

DRUG

Dexamethasone

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, Basking Ridge

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Commack, Commack

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02697383 - Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study | Biotech Hunter | Biotech Hunter